“…For chemical treatments, the glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonist MK-801, the dopamine D1 receptor antagonist SCH23390, and the epilepsy and bipolar disorder drug valproic acid have been used to evoke ASD-like symptoms in rodents [ 203 ] and have also been applied to zebrafish for modeling ASD [ 204 , 205 ]. For genetic modeling analogous to rodent ASD models which were established by overexpressing ASD-risk genes such as kctd13 , bbs7 , and cep290 , or by knocking down/knocking out dyrk1a , coro1a , fam57ba , gdpd3 , hirip3 , kif22 , maz , ppp4ca , shank3 , fmr1 , and cntnap2 , zebrafish ASD models have been successfully generated by targeting a similar set of ASD-susceptibility genes using genetic manipulations (reviewed in [ 126 , 206 ]).…”